NasdaqGS - Nasdaq Real Time Price USD

Blueprint Medicines Corporation (BPMC)

100.51

-1.18

(-1.16%)

As of 12:28:18 PM EDT. Market Open.

Blueprint Medicines Corporation Just Reported A Surprise Profit And Analysts Updated Their Estimates

Shareholders of Blueprint Medicines Corporation ( NASDAQ:BPMC ) will be pleased this week, given that the stock price...

Simply Wall St. 15 days ago

BPMC
-1.16%
Blueprint Medicines First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

Blueprint Medicines ( NASDAQ:BPMC ) First Quarter 2025 Results Key Financial Results Revenue: US$149.4m (up 56% from 1Q...

Simply Wall St. 16 days ago

BPMC
-1.16%
Blueprint Medicines Stock Up Despite Lower-Than-Expected Q1 Earnings

BMPC's first-quarter earnings and sales miss estimates. However, shares rally on raised Ayvakit sales guidance for 2025.

Zacks 17 days ago

BPMC
-1.16%
Blueprint Medicines Corp (BPMC) Q1 2025 Earnings Call Highlights: Strong AYVAKIT Revenue Growth ...

Blueprint Medicines Corp (BPMC) reports a 61% increase in AYVAKIT revenue and raises its annual revenue guidance, showcasing robust commercial performance and strategic growth initiatives.

GuruFocus.com 17 days ago

BPMC
-1.16%
Q1 2025 Blueprint Medicines Corp Earnings Call

Q1 2025 Blueprint Medicines Corp Earnings Call

Thomson Reuters StreetEvents 17 days ago

BPMC
-1.16%
Blueprint Medicines (BPMC) Reports Q1 Loss, Lags Revenue Estimates

Blueprint Medicines (BPMC) delivered earnings and revenue surprises of -76.19% and 8.04%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks 18 days ago

BPMC
-1.16%
Blueprint Medicines: Q1 Earnings Snapshot

CAMBRIDGE, Mass. AP) — Blueprint Medicines Corp. BPMC) on Thursday reported first-quarter profit of $496,000.

Associated Press Finance 18 days ago

BPMC
-1.16%
Blueprint Medicines Reports First Quarter 2025 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance

Blueprint Medicines Corporation (Nasdaq: BPMC) today reported financial results, provided a business update for the first quarter ended March 31, 2025, and provided corporate updates.

PR Newswire 18 days ago

BPMC
-1.16%
Blueprint Medicines to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 1, 2025, to report its first quarter 2025 financial results and provide a corporate update.

PR Newswire 24 days ago

BPMC
-1.16%
Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: Should You Buy?

Blueprint Medicines (BPMC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 25 days ago

BPMC
-1.16%

INCY
Blueprint Medicines Corporation (BPMC): Among Takeover Rumors Hedge Funds Are Buying

We recently published a list of 20 Takeover Rumors Hedge Funds Are Buying. In this article, we are going to take a look at where Blueprint Medicines Corporation (NASDAQ:BPMC) stands against other takeover rumor stocks hedge funds are buying. Hedge funds tend to pile up on a stock that gains or is expected to gain […]

Insider Monkey 25 days ago

BPMC
-1.16%
3 High Growth Tech Stocks In The US Market

In the current U.S. market landscape, significant volatility has been observed as major indices like the Dow Jones and Nasdaq Composite experience sharp declines due to ongoing tariff concerns and uncertainty surrounding Federal Reserve policies. In this environment, identifying high-growth tech stocks requires careful consideration of their resilience to geopolitical tensions and their ability to innovate amidst economic challenges.

Simply Wall St. 27 days ago

BPMC
-1.16%

PSTG

JBL
Adma Biologics (ADMA) Moves 7.8% Higher: Will This Strength Last?

Adma Biologics (ADMA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks last month

ADMA

BPMC
-1.16%
Blueprint Medicines to Present at 24th Annual Needham Virtual Healthcare Conference

Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that company management will participate virtually in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025, at 12:45 p.m. ET.

PR Newswire last month

BPMC
-1.16%
Is Blueprint Medicines (BPMC) One of the Best Mid Cap Biotech Stocks to Buy?

We recently published a list of the 10 Best Mid Cap Biotech Stocks to Buy. In this article, we are going to take a look at where Blueprint Medicines Corporation (NASDAQ:BPMC) stands against the other best mid cap biotech stocks to buy. Is the Biotech Sector Oversaturated? On March 6, Jared Holz, Mizuho health care […]

Insider Monkey last month

BPMC
-1.16%
Is Blueprint Medicines Corporation (BPMC) a Promising Biotech Stock According to Wall Street Analysts

We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we are going to look at where Blueprint Medicines Corporation (NASDAQ:BPMC) stands against other biotech stocks. Biotech Sector Set for Growth Amid Innovation and Investor Interest The biotechnology sector is gaining new momentum with better market […]

Insider Monkey last month

BPMC
-1.16%
Blueprint Medicines (BPMC): Among Stocks Insiders Are Selling In March

We recently published a list of 10 Stocks Insiders Are Selling In March. In this article, we are going to take a look at where Blueprint Medicines Corporation (NASDAQ:BPMC) stands against other stocks Insiders are selling in March. Wall Street experienced a challenging week, marked by turbulence as the broader market entered a correction, declining […]

Insider Monkey last month

BPMC
-1.16%
Reddit initiated, Netflix upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: MoffettNathanson upgraded Netflix (NFLX) to Buy from Neutral with a price target of $1,100, up from $850. The firm believes the company’s ability to monetize its engagement remains underappreciated. William Blair upgraded DocuSign (DOCU) to Outperform from Market Perform. The firm is bullish on the mar

TipRanks 2 months ago

EMR

NFLX

CION
Exploring High Growth Tech Stocks In The US Market March 2025

Over the last 7 days, the United States market has dropped 4.4%, yet it remains up by 7.5% over the past year, with earnings projected to grow by 14% annually. In this context of fluctuating performance and optimistic earnings forecasts, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation potential and adaptability to changing market dynamics.

Simply Wall St. 2 months ago

CYBR

RZLV

RZLVW
Blueprint Medicines Highlights Leading Portfolio of Mast Cell-Targeted Therapies at 2025 AAAAI / WAO Joint Congress

Blueprint Medicines Corporation (Nasdaq: BPMC) today announced data presentations reflecting its ongoing efforts to innovate the treatment of mast cell-driven diseases. The presentations include three-year median follow-up data from the registrational PIONEER trial demonstrating the strong long-term efficacy and safety of AYVAKIT® (avapritinib) in patients with indolent systemic mastocytosis (ISM), and real-world evidence further characterizing the substantial burden of the disease, highlighting

PR Newswire 2 months ago

BPMC
-1.16%

Performance Overview

Return	BPMC	S&P 500 (^GSPC)
YTD	+15.24%	+1.21%
1-Year	-4.23%	+12.25%
3-Year	+76.47%	+52.61%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Blueprint Medicines Corporation (BPMC)

Blueprint Medicines Corporation Just Reported A Surprise Profit And Analysts Updated Their Estimates

Blueprint Medicines First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

Blueprint Medicines Stock Up Despite Lower-Than-Expected Q1 Earnings

Blueprint Medicines Corp (BPMC) Q1 2025 Earnings Call Highlights: Strong AYVAKIT Revenue Growth ...

Q1 2025 Blueprint Medicines Corp Earnings Call

Blueprint Medicines (BPMC) Reports Q1 Loss, Lags Revenue Estimates

Blueprint Medicines: Q1 Earnings Snapshot

Blueprint Medicines Reports First Quarter 2025 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance

Blueprint Medicines to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: Should You Buy?

Blueprint Medicines Corporation (BPMC): Among Takeover Rumors Hedge Funds Are Buying

3 High Growth Tech Stocks In The US Market

Adma Biologics (ADMA) Moves 7.8% Higher: Will This Strength Last?

Blueprint Medicines to Present at 24th Annual Needham Virtual Healthcare Conference

Is Blueprint Medicines (BPMC) One of the Best Mid Cap Biotech Stocks to Buy?

Is Blueprint Medicines Corporation (BPMC) a Promising Biotech Stock According to Wall Street Analysts

Blueprint Medicines (BPMC): Among Stocks Insiders Are Selling In March

Reddit initiated, Netflix upgraded: Wall Street’s top analyst calls

Exploring High Growth Tech Stocks In The US Market March 2025

Blueprint Medicines Highlights Leading Portfolio of Mast Cell-Targeted Therapies at 2025 AAAAI / WAO Joint Congress

Performance Overview